Table 1: Current therapies for BCR-ABL1 negative MPN patients to be combined with JAK2 inhibitors.

DrugTargetResultsJAK2V617F loadReference

JAK2 inhibitors
 INCB018424
 Ruxolitinib
JAK2, JAK1 >50% reduction in splenomegaly and constitutional symptomsJAK2V617F load marginally reduced Verstovsek et al. [29]
 TG101348 or
 SAR302503
JAK2, FLT3 Reduction in splenomegalyJAK2V617F load significantly reducedPardanani et al. [34]
CYT387 JAK2, JAK1, TYK2 In a murine model, normalized erythrocytes, leukocytes, spleen size, and levels of inflammatory cytokinesJAK2V617F load reduced Tyner et al. [35]
CEP-701
Lestaurtinib
JAK2, FLT3 Reduction in splenomegalyJAK2V617F load no reduced Hexner et al. [36]
Santos et al. [37]

Immunomodulators
 Interferon-alpha Stromal cells Inhibit cytokine signalling, proliferation and angiogenesis Unknown Kiladjian et al. [43]
 Thalidomide Stromal cells Inhibition of angiogenesis Unknown Jabbour et al. [45]
 Lenalidomide Stromal cells Inhibition of angiogenesis Unknown Jabbour et al. [45]
 Pomalidomide Stromal cells Inhibition of angiogenesis Unknown Begna et al. [46]

Other
 HydroxycarbamideJAK2 mutant burden Inhibition of proliferationJAK2V617F load significantly reduced Besses et al. [47]
 Histone
 post-translationa
 modificators
JAK2 nuclear Depletion of JAK2V617F autophosphorylation, apoptosis in vitro Unknown Wang et al. [26]